Clinical trial
A Research Study to Evaluate BLX-7006 in Healthy Adults
Opening soon · Phase 1 · 1 countries · Registry ID NCT07140055
What this study is about
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.
Basic eligibility
Full registry criteria
Treatments and study arms
BLX-7006
BLX-7006 Single or Multiple doses administered orally as a tablet
Placebo
Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.
Primary outcomes
The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of adverse effects in subjects, as assessed according to CTCAE v5.0. The number of participants who experience an AE will be reported.
The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of SAE in subjects, as assessed according to CTCAE v5.0. The number of participants who experience a SAE will be reported.
The safety and tolerability of oral BLX-7006 administration will be evaluated based on the incidence of TRAEs in subjects, as assessed according to CTCAE v5.0. The number of participants who experience a TRAE will be reported.
Study locations
1 locations were listed when this page was built. The first 40 are shown.